Trial Profile
Phase I-II Study of Vinblastine in Combination With Nilotinib in Children, Adolescents, and Young Adults With Refractory or Recurrent Low-Grade Glioma
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 01 Jun 2022
Price :
$35
*
At a glance
- Drugs Nilotinib (Primary) ; Vinblastine
- Indications Glioma; Tumours
- Focus Therapeutic Use
- Acronyms VINILO
- Sponsors Novartis
- 24 May 2022 Status changed from active, no longer recruiting to discontinued.
- 24 May 2022 Status changed from active, no longer recruiting to discontinued.
- 19 Feb 2022 This trial has been completed in Denmark (End Date: 25 Apr 2021), according to European Clinical Trials Database record.